Herika Almeida Vidal

Ms. Herika Almeida Vidal

Universidade Federal de São Carlos - UFSCar
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2022 in Molecules
Verified
Journal Article
Open access
PDF file
Everton Machado da SilvaEverton Machado da Silva
Everton Machado da Silva
Herika Almeida VidalHerika Almeida Vidal
Herika Almeida Vidal
MJMarcelo Augusto Pereira Januário
Marcelo Augusto Pereira Januário
Arlene Gonçalves CorrêaArlene Gonçalves Corrêa
Arlene Gonçalves Corrêa
BINOL derivatives have shown relevant biological activities and are important chiral ligands and catalysts. Due to these properties, their asymmetric synthesis has attracted the interest of the scientific community. In this work, we present an overview of the most efficient methods to obtain chiral BINOLs, highlighting the use of metal complexes and organocatalysts as well as kinetic resolution. Further derivatizations of BINOLs are also discussed.

4 November 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Everton Machado da SilvaEverton Machado da Silva
Everton Machado da Silva
Herika Almeida VidalHerika Almeida Vidal
Herika Almeida Vidal
Arlene Gonçalves CorrêaArlene Gonçalves Corrêa
Arlene Gonçalves Corrêa
Viral infections cause many severe human diseases, being responsible for remarkably high mortality rates. In this sense, both the academy and the pharmaceutical industry are continuously searching for new compounds with antiviral activity, and in addition, face the challenge of developing greener and more efficient methods to synthesize these compounds. This becomes even more important with drugs possessing stereogenic centers as highly enantioselective processes are required. In this minireview, the advances achieved to improve synthetic routes efficiency and sustainability of important commercially antiviral chiral drugs are discussed, highlighting the use of organocatalytic methods.

7 July 2023 in Biophysica
Verified
Journal Article
Open access
PDF file
IMIngrid Vieira Machado
Ingrid Vieira Machado
LNLuiz F. N. Naves
Luiz F. N. Naves
JCJean Custodio
Jean Custodio
Herika Almeida VidalHerika Almeida Vidal
Herika Almeida Vidal
JQJAQUELINE EVANGELISTA DE QUEIROZ
JAQUELINE EVANGELISTA DE QUEIROZ
GAGilberto Aquino
Gilberto Aquino
Cancer resistance to chemotherapy and radiation therapies presents significant challenges, necessitating the exploration of alternative approaches. Targeting specific proteins at the molecular level, particularly their active sites, holds promise in addressing this issue. We investigated the potential of 4′-methoxy-2-nitrochalcone (MNC) as an MCL-1 inhibitor, examining its chemical and structural characteristics to elucidate its biological activity and guide the selection of potential candidates. We conducted a docking study, followed by synthesis, structural characterization, theoretical calculations, and in vitro experiments to comprehensively evaluate MNC. The docking results revealed MNC’s excellent binding within the active site of MCL-1. At 50 µM, MNC demonstrated 99% inhibition of HCT116 cell proliferation, with an IC50 value of 15.18 µM after 24 h. Treatment with MNC at 30.36 and 15.18 µM resulted in reduced cell density. Notably, MNC exhibited marked cytotoxicity at concentrations of 15.58 µM and 7.79 µM, inducing high frequencies of plasma membrane rupture and apoptosis, respectively. Our findings highlight the significant biological potential of MNC as an MCL-1 inhibitor. Furthermore, we propose exploring chalcones with hydrogen bond acceptor substituents as promising candidates for studying inhibitors targeting this protein. In conclusion, our study addresses the challenge of cancer resistance by investigating MNC as an MCL-1 inhibitor. Through detailed characterization and experimental validation, we establish the efficacof MNC in inhibiting cell proliferation and inducing cytotoxic effects. These results underscore the potential of MNC as a valuable therapeutic agent and suggest the use of chalcones with hydrogen bond acceptor substituents as a basis for developing novel MCL-1 inhibitors.

14 October 2021 in Preprints.org
Verified
Preprint
Open access
ACArlene Gonçalves Corrêa
Arlene Gonçalves Corrêa
Everton Machado da SilvaEverton Machado da Silva
Everton Machado da Silva
Herika Almeida VidalHerika Almeida Vidal
Herika Almeida Vidal
Viral infections inflict many serious human diseases, being responsible for remarkably high mortality rates. In this sense, both the academy and the pharmaceutical industry are continuously searching for new compounds with antiviral activity, and in addition, face the challenge of developing greener and more efficient methods to synthesize these compounds. This becomes even more important with drugs possessing stereogenic centers as highly enantioselective processes are required. In this minireview, the advances achieved to improve synthetic routes efficiency and sustainability of important commercially antiviral chiral drugs are discussed, highlighting the use of organocatalytic methods.